Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
11:36am, Friday, 03'rd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biote
25 Stocks Moving in Friday's Pre-Market Session
11:15am, Friday, 03'rd Apr 2020
Gainers
electroCore, Inc. (NASDAQ: ECOR) shares rose 83.5% to $1.37 in pre-market trading after the company submitted emergency use authorization application to allow study and...
Fate Therapeutics (NASDAQ:FATE) Given "Buy" Rating at Mizuho
09:46am, Friday, 03'rd Apr 2020
Fate Therapeutics (NASDAQ:FATE)‘s stock had its “buy” rating restated by equities researchers at Mizuho in a report issued on Friday, AnalystRatings.com reports. They currently have a $40.00 tar
Fly Intel: Wall Street's top stories for Friday MMM;TSLA;BBBY;BAC;JPM;WFC;C;AMZN;WMT;FATE;JNJ;INCY;MIC;AEHR;CHWY
09:30am, Friday, 03'rd Apr 2020
Fly Intel: Wall Street's top stories for Friday MMM TSLA BBBY BAC JPM WFC C AMZN WMT FATE JNJ INCY MIC AEHR CHWY
Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities
08:11am, Friday, 03'rd Apr 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Fate Therapeutics (FATE) today and set a price target of $40.00. The company's shares
Fate Therapeutics (FATE) Receives a Buy from Mizuho Securities
08:11am, Friday, 03'rd Apr 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Fate Therapeutics (
FATE
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Thursday
Fate Therapeutics up 23% after hours on J&J cell therapy deal
09:00pm, Thursday, 02'nd Apr 2020
Fate Therapeutics (NASDAQ:FATE) inks a global collaboration and option agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech aimed at developing cell therapies for cancer.The partnershi
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
08:46pm, Thursday, 02'nd Apr 2020
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
08:46pm, Thursday, 02'nd Apr 2020
ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell...
Fate Therapeutics Announces First Patient Treated In First-in-Human Clinical Trial Of FT596 And Provides Corporate Update
08:45pm, Thursday, 02'nd Apr 2020Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
08:45pm, Thursday, 02'nd Apr 2020
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update
08:45pm, Thursday, 02'nd Apr 2020
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the...
Fly Intel: After-Hours Movers PLAY;FATE;TSLA;ZUMZ;INCY;BBBY;PTON;CAKE;AEHR;CHWY;DTIL
12:02pm, Thursday, 02'nd Apr 2020
Fly Intel: After-Hours Movers PLAY FATE TSLA ZUMZ INCY BBBY PTON CAKE AEHR CHWY DTIL
